Gluformin G2 Forte New Tablet PR is a combination oral hypoglycemic agent containing Glimepiride 2 mg and Metformin 1000 mg, indicated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class drug, stimulates pancreatic beta cells to release insulin, thereby enhancing insulin secretion and improving glycemic control. Metformin, a biguanide, primarily reduces hepatic glucose production and improves peripheral insulin sensitivity, contributing to decreased blood glucose levels. The combination of these two agents offers complementary mechanisms of action, providing effective glycemic control in patients inadequately controlled by diet and exercise alone. Gluformin G2 Forte New Tablet PR is intended for use as part of a comprehensive diabetes management plan, including diet modification and regular physical activity. It is contraindicated in patients with type 1 diabetes, diabetic ketoacidosis, severe renal or hepatic impairment, and conditions predisposing to hypoxia. Common adverse effects may include gastrointestinal disturbances such as nausea, vomiting, and diarrhea, as well as hypoglycemia, particularly due to the sulfonylurea component. Regular monitoring of blood glucose levels and renal function is recommended during therapy. Dose adjustments should be individualized based on therapeutic response and tolerability. This medication should be prescribed and used under medical supervision.